Lymphangioma
7
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma
Institution of an Italian Registry and Biobank for Biological Sample Collection
Clinical Characteristics of Lymphatic Malformations
Compassionate Use of BYL 719 Alpelisib
A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations